Subgroup analyses from DAPA-HF and EMPEROR-Reduced evaluated the effects of dapagliflozin and empagliflozin on CV and kidney outcomes according to baseline kidney function in patients with HFrEF.

Tirzepatide, a dual glucose-dependent insulinotropic peptide/GLP-1 receptor agonist (GIP/GLP-1RA), significantly improved glycemic control and reduced body weight in patients with T2DM.

A post hoc analysis of the LEADER trial showed that a reduction in albuminuria was associated with fewer CV and renal outcomes in patients with T2DM. Frederik Persson presents the results of this analysis.

This exploratory analysis from DAPA-HF showed that dapagliflozin, compared to placebo, reduced new-onset T2DM in patients with HFrEF without diabetes at baseline.

This study investigated the relative risk of more than 50 clinical risk factors and biomarkers with incident CHD in 4 age groups in women.

A risk score based on elevated levels of hs-cTnT, NT-proBNP, and hs-CRP, and presence of left ventricular hypertrophy can stratify incident HF risk in patients with dysglycemia without CVD.

5 Things a cardiologist needs to know about GLP-1 RA Prof. Deanfield discusses the changing paradigm for managing cardiometabolic risk in clinical practice by the emergence of diabetes. He states that GLP-1 receptor agonists will be an important component of treatment strategies.

Three speakers discuss several aspects of CV risk in diabetes: the role for primary care in reducing CV risk factors, the role of GLP-1RAs in reducing CV risk and recommendations in the newest ESC guidelines on diabetes and CVD.

This educational program consists of three presentations on residual CVD risk with a focus on triglycerides and triglyceride-rich lipoproteins.

Triglycerides and remnant-c, but not LDL-c and HDL-c, were associated with MACE in a primary prevention cohort of high CV risk subjects with high prevalence of diabetes and obesity.

5 Things a cardiologist needs to know about GLP-1RA Prof. Verma discusses the CV results of clinical trials with GLP-1RAs and how these translate to CV protection in T2DM.

A subanalysis of REDUCE-IT showed that icosapent ethyl in high CV risk patients with persistently high TG levels reduced the risk for first and subsequent revascularization.